Dishman Carbogen Share Price

Dishman Carbogen Amcis Limited (Dishman Carbogen Amcis) is a global pharmaceutical company in India, primarily engaged in providing contract research and manufacturing services (CRAMS) to the pharmaceutical and healthcare industries. The company supplies active pharmaceutical ingredients (APIs), contract development and manufacturing organization (CDMO) services, specialty chemicals, vitamin D analogues, and disinfectants to clients worldwide. The Dishman Carbogen Amcis share price today on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Dishman Carbogen Amcis stock price often mirrors shifts in pharmaceutical outsourcing demand, spending patterns from the biotech and pharma sectors, and investor views on the CDMO sector’s growth prospects. Factors such as the pace of order book expansion, competitive intensity from other CRAMS providers, raw material price fluctuations, and regulatory approvals from agencies like the US FDA influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Dishman Carbogen stock price movements.

Dishman Carbogen live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Dishman Carbogen live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Dishman Carbogen share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Dishman Carbogen Amcis Limited Company Fundamentals

a. Company Background

Dishman Carbogen Amcis Limited was incorporated in 2007. The company’s registered office is located in Ahmedabad, Gujarat. The company was originally established as a provider of contract research and manufacturing services (CRAMS) to the pharmaceutical industry. A significant milestone was the acquisition of Carbogen Amcis in 2006, which helped transform the company into a global pharmaceutical pioneer. The company’s primary activity involves providing end-to-end pharmaceutical services, from early-stage drug development to commercial-scale manufacturing. It initially focused on establishing manufacturing capabilities for APIs and intermediates before gradually expanding into specialty chemicals, vitamin D analogues, and disinfectants. Dishman Carbogen Amcis supplies CRAMS, active pharmaceutical ingredients (APIs), specialty chemicals, vitamin D analogues, and disinfectants to clients globally. The company has played a significant role in India’s pharmaceutical outsourcing industry. Over the years, Dishman Carbogen Amcis has significantly expanded its global footprint, now operating 25 multipurpose manufacturing sites and 28 R&D labs across India, Switzerland, the UK, France, China, and the Netherlands. It operates in a highly competitive environment, with quality certifications from the US FDA and other international regulators governing its market position. As of March 31, 2025, the company had 18 subsidiaries. The company has consistently focused on enhancing its capabilities to meet the growing demand for pharmaceutical outsourcing services.

b. Product Lines

• Contract Research and Manufacturing Services (CRAMS) including molecule development, clinical trial materials, and long-term manufacturing partnerships

• Active pharmaceutical ingredients (APIs) for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes

• Contract development and manufacturing organization (CDMO) services from early-stage drug development to commercial-scale production

• Specialty chemicals including quaternary ammonium compounds (quats), phosphoranes, and wittig reagents

• Vitamin D analogues, cholesterol, and lanolin-related products

• Generic APIs for the pharmaceutical industry

• Health and personal care solutions including antimicrobial agents like Octenidine HCl, Cetrimide powder, and Benzalkonium Chloride (BKC) 50%

• Sterile injectables and softgel formulations

• Hand and body wash, sanitisers, and antiseptics for personal care applications

• Intermediate chemicals and pharmaceutical intermediates

c. Company Revenue Model

• Primary revenue from Contract Research and Manufacturing Services (CRAMS), which contributed 84.6% of the company’s turnover in FY25

• Revenue from Marketable Molecules segment including specialty chemicals, vitamins and analogues, generic APIs, and disinfectants, which contributed 15.4% of turnover in FY25

• CDMO revenue from development projects and commercial manufacturing partnerships with global pharmaceutical leaders including Novartis, Takeda, Eisai, Johnson & Johnson, and Seagen

• Volume-driven revenue based on number of projects, clinical trial materials produced, and long-term manufacturing contracts

• Pricing determined by project complexity, regulatory compliance requirements, and long-term supply agreements

• Expanding order book of about ₹1,250 crore and 14 molecules in advanced Phase III trials contributing to new revenue streams

• Focus on increasing high-value CDMO projects to improve margins

• Revenue from both domestic operations in India and international operations across Switzerland, UK, France, China, and the Netherlands

• Seasonal variations in pharmaceutical development cycles affecting revenue patterns

• Regulatory approvals from agencies like US FDA influencing revenue stability and facility utilization

d. Geographic Presence

• Headquartered in Ahmedabad, Gujarat with registered office at Swastik Cross Road, Navrangpura, Ahmedabad – 380009

• Strong global presence across six countries with 25 multipurpose manufacturing facilities located in India, Switzerland, the Netherlands, France, the United Kingdom, and China

• Operates 28 R&D labs worldwide supporting drug development from early-stage to commercial production

• Two large manufacturing sites near Ahmedabad in India and one site in Veenendaal, Netherlands

• Subsidiary presence includes CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG, and Dishman Biotech Ltd.

• Seven international sales offices serving a wide global client base

• Serves pharmaceutical and biotechnology clients across multiple countries with European facilities operating at around 80% capacity and Indian units at about 30% capacity

• Focus on expanding global footprint through strategic acquisitions and partnerships

• Operations primarily concentrated in India and Europe with growing presence in China and Singapore

e. Key Milestones

• 1983: Company founded (original incorporation year)

• 2006: Acquisition of Carbogen Amcis, transforming the company into a global pharmaceutical pioneer

• 2007: Incorporated as Dishman Carbogen Amcis Limited on July 17, 2007

• 2017: Trading of Dishman Carbogen Amcis shares on BSE and NSE commenced on September 21, 2017

• 2020: Name changed from IFMR Capital Finance Limited to Northern Arc Capital Limited in February 2018

• 2025: Received GMP certification for its French sterile injectables facility and new drug manufacturing license from Chinese regulatory body for its Shanghai site

• 2025: Bavla site received Establishment Inspection Report (EIR) from the US FDA, indicating closure of inspection

• 2025: Consolidated revenue grew 3.7% year-on-year to ₹2,711.5 crore in FY25

f. Industry Perspective

Dishman Carbogen Amcis Limited operates in the Contract Research and Manufacturing Services (CRAMS) and pharmaceutical outsourcing industry, which is part of India’s pharmaceutical sector. Globally, the CDMO market was valued at approximately USD 170 billion in 2024, with the Asia-Pacific region being the fastest-growing market, accounting for around 35% of global demand. The global pharmaceutical CRAMS market is projected to grow at a CAGR of approximately 7.5% from 2025 to 2030, driven by increasing R&D outsourcing by big pharma companies. In India, the CRAMS market is poised for substantial growth as the nation strengthens its position as a global pharmaceutical outsourcing hub. According to industry reports, the Indian CRAMS market was valued at USD 12 billion in 2024 and is projected to reach USD 25 billion by 2028, growing at a CAGR of 15-16% during this period. The pharmaceutical outsourcing sector in India contributes to approximately 5% of the global CRAMS market. The government aims to increase India’s share in global pharmaceutical manufacturing to 15% by 2030, creating significant opportunities for CRAMS providers. The CDMO segment currently accounts for about 40% of the total CRAMS market in India. Demand is driven by government initiatives such as the Production Linked Incentive (PLI) Scheme for pharmaceuticals, the National Pharmaceutical Policy, and increasing R&D expenditure by global pharmaceutical companies. Key challenges include regulatory compliance costs, intense competition from global CDMOs, raw material price volatility, and talent acquisition and retention in specialized areas.

Dishman Carbogen Amcis Limited Stock Market Presence: Listings & Index Representation

Dishman Carbogen Amcis is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol DCAL (with NSE Code DCALEQ) and on the Bombay Stock Exchange (BSE) with the scrip code 540701. Its listing on both exchanges ensures that the Dishman Carbogen Amcis share price is accessible to a wide investor base, encompassing both retail and institutional market participants. Trading of Dishman Carbogen Amcis shares on BSE and NSE commenced on September 21, 2017. The company forms part of several benchmark indices that represent broad market segments. Dishman Carbogen Amcis is included in indices such as BSE AllCap, BSE Healthcare, BSE MidSmallCap, BSE SmallCap, Nifty Microcap 250, and Nifty Total Market. Being represented in multiple indices enhances the visibility and liquidity of the Dishman Carbogen Amcis share price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Dishman Carbogen Amcis in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the Dishman Carbogen Amcis price to corporate and industry developments. The company’s ISIN code is INE385W01011 and face value is ₹2 per share.

Dishman Carbogen Amcis Limited Stock Performance and Share Price History

The Dishman Carbogen Amcis price has exhibited significant volatility over the past decade, shaped by the company’s evolution from a domestic API manufacturer into a global CDMO leader. The Dishman Carbogen Amcis share price recorded a negative total return of approximately 27.0% over the last 1 year, underperforming broader market indices and reflecting near-term headwinds including regulatory challenges and margin compression. The Dishman Carbogen Amcis share price delivered a 10-year average YTD return of +11.45%, demonstrating moderate long-term wealth creation despite recent underperformance. The Dishman Carbogen Amcis share price reached a 52-week high of 321.95 and a 52-week low of 128.50, indicating a wide trading range and substantial price fluctuations. The Dishman Carbogen Amcis share price recorded a strong rally in 2023, delivering a substantial positive annual return of 80.1%, while the subsequent period has seen the Dishman Carbogen Amcis stock price moderate and correct from its peak levels. The Dishman Carbogen Amcis share price has shown a 1-month return of approximately -7.4% and a 3-month return of -40.8%, indicating recent consolidation.

The Dishman Carbogen Amcis stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 178.81% quarter-on-quarter growth in net profit in recent quarters, the Dishman Carbogen Amcis stock price showed a positive reaction. The Dishman Carbogen Amcis price has shown a pattern of strong positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Dishman Carbogen Amcis stock price. Corporate developments, including strategic announcements such as the co-investment agreement of CHF 25 million to expand ADC linker capacity in Switzerland and the receipt of GMP certification for its French sterile injectables facility, have also influenced short-term fluctuations in the Dishman Carbogen Amcis share price. The Dishman Carbogen Amcis share price has shown a 5-year return of 5.2% according to some sources, while the 3-year return stands at 4.3%, reflecting the volatility in the stock. The Dishman Carbogen Amcis share price reached its 52-week high of 321.95 before declining to its 52-week low of 128.50, reflecting the volatility inherent in the pharmaceutical outsourcing space. The Dishman Carbogen Amcis share price has shown a year-to-date return of -38.6% as of April 2026, indicating continued pressure in the current fiscal year. Comprehending these patterns in the Dishman Carbogen Amcis price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Dishman Carbogen Amcis stock price movements illustrate how industry fundamentals, regulatory policy cycles, and investor expectations converge in market pricing.

The Dishman Carbogen Amcis share price has shown distinct seasonal patterns over the past decade. The best performing month historically was April with a total return of +11.98% (based on average past 10 years), while the worst performing month was September with a negative return of -5.23%. Historically, 4 out of 8 years (50%) have shown positive returns for the March–May period, with the average return standing at +11.58% for that 60-day window. In terms of annual performance, the Dishman Carbogen Amcis share price delivered its strongest annual return of 80.1% in 2023, followed by a positive return of 76.7% in 2020, and 51.1% in 2024. The stock recorded negative annual returns in 2019 (-63.8%), 2022 (-52.9%), 2018 (-1.23% for specific period), and 2025 (-13.2%). The Dishman Carbogen Amcis share price has demonstrated that the stock tends to perform better in periods of strong pharmaceutical outsourcing demand and supportive regulatory approvals, while underperforming during phases of regulatory uncertainty and intense competition. The Dishman Carbogen Amcis stock price has shown a 1-year return of -27.0% according to some sources. The Dishman Carbogen Amcis stock price has shown continued weakness in the current trading period, reflecting the ongoing challenges in the pharmaceutical CDMO sector.

Dishman Carbogen Amcis Limited Investor Relevance and Role in Portfolio

Dishman Carbogen Amcis holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical outsourcing sector with a focus on the CDMO and CRAMS segment. The company’s strong presence in contract research and manufacturing, APIs, specialty chemicals, and vitamin D analogues aligns it with investment strategies that value innovation and regulatory compliance. The Dishman Carbogen Amcis share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor order book indicators and regulatory approval metrics when evaluating allocation decisions.

Institutional stakeholders play a significant role in Dishman Carbogen Amcis’s ownership profile, with notable long term investment entities such as Adimans Technologies LLP (promoter), Mukul Mahavir Agrawal, and various foreign institutional investors among key shareholders identified in institutional holdings data. Mutual fund holders of Dishman Carbogen Amcis encompass those that seek pharmaceutical and CDMO exposure. The Dishman Carbogen Amcis share price has shown institutional participation, with Foreign Institutional Investors (FIIs) holding 7.66% and Domestic Institutional Investors (DIIs) holding 1.27% as of December 2025. The Dishman Carbogen Amcis stock price’s beta reflects that the company’s diversified pharmaceutical services nature and established global client relationships may provide some stability, though the CRAMS sector remains sensitive to regulatory changes and economic cycles.

Based on data, Dishman Carbogen Amcis exhibits varying levels of beta and volatility across different measurement periods. The long-term beta (5Y monthly) stands at 1.27, indicating that the stock is generally more volatile than the broader market over an extended period. Based on data, the daily-one month beta is 1.8554, suggesting higher sensitivity than the market, while the daily-three month beta shows moderate correlation. The weekly-one year beta is 0.9300, showing near-market sensitivity. Based on data, the weekly-two year beta shows moderate fluctuations. Supporting statistics include mean values across different periods and standard deviations ranging from moderate to high levels. The weekly volatility is approximately 9% which has been stable over the past year but remains higher than 75% of Indian stocks. Overall, Dishman Carbogen Amcis demonstrates a mixed volatility profile with beta values suggesting the stock has periods of both lower and higher sensitivity to market movements, with weekly volatility of approximately 9% that has been stable over the past year.

The Dishman Carbogen Amcis share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Dishman Carbogen Amcis stock price’s beta reflects that the company’s diversified pharmaceutical services nature and established global client relationships may provide some stability, though the CRAMS sector remains sensitive to regulatory changes and economic cycles.

Dishman Carbogen Amcis Limited Sectoral Relevance and Peer Positioning

The sector relevance of Dishman Carbogen Amcis is anchored in its role within the broader Indian pharmaceutical outsourcing and CRAMS industry, where it competes with other pharmaceutical service providers. As part of this industry, the company’s strategic positioning connects contract research and manufacturing, APIs, specialty chemicals, and vitamin D analogues for global pharmaceutical and biotechnology clients. Competitors in the CDMO and CRAMS segment include companies such as Sun Pharmaceutical Industries Limited, Divi’s Laboratories Limited, Torrent Pharmaceuticals Limited, Cipla Limited, Aarti Drugs Limited, Sequent Scientific Limited, Hikal Limited, Unichem Laboratories Limited, RPG Life Sciences Limited, Gujarat Themis Biosyn Limited, Orchid Pharma Limited, Gufic Biosciences Limited, and Advanced Enzyme Technologies Limited. Firms with parallels in either service scale or customer reach are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Dishman Carbogen Amcis P/E ratio have shown variations over different periods. The mean historical PE Ratio over the last ten years has varied significantly, with the current P/E ratio of 21.04 having changed with respect to the historical average. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction. Dishman Carbogen Amcis earnings have shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from order book expansion and strategic acquisitions supported directional improvement in earnings during favourable conditions, while cyclical headwinds from regulatory compliance costs and competitive pressures have moderated earnings momentum. Dishman Carbogen Amcis earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Dishman Carbogen Amcis market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical outsourcing market.

Over years, the Dishman Carbogen Amcis market cap has followed a pattern of growth followed by moderation. From fiscal year 2019 onwards, the company’s market cap showed an increasing trend, reflecting strong investor confidence following the Carbogen Amcis acquisition integration. The market cap increased from approximately ₹5,109 crore in 2018 to a peak of ₹28,966 crore in 2022, before moderating to approximately ₹23,110-34,146 crore in recent periods. As of recent data, market capitalization stands at approximately ₹2,379 crore (BSE) to ₹3,304 crore (NSE) depending on the source. This decrease mirrors the correction in the Dishman Carbogen Amcis share price and the broader performance of the pharmaceutical outsourcing sector relative to broader market indices.

Dishman Carbogen Amcis earnings over the past ten years has been characterised by a period of growth followed by recent volatility. Net income showed a generally increasing trend, with reported net profit rising from ₹145 crore in 2017 to ₹155 crore in 2018, ₹210 crore in 2019, before declining to ₹159 crore in 2020, and turning into losses of -₹165 crore in 2021, before recovering to ₹18 crore in 2022, and again turning negative at -₹30 crore in 2023, -₹153 crore in 2024, and ₹3 crore in 2025. This recent earnings volatility reflects the impact of demand fluctuations, increased competitive intensity, and regulatory compliance costs on the company’s profitability.

Dishman Carbogen Amcis EPS has shown significant variation over the past decade. The diluted EPS growth rate has shown extreme variation, with EPS of ₹9.92 in 2011, ₹9.58 in 2018, ₹13.03 in 2019, ₹10.10 in 2020, -₹10.53 in 2021, ₹1.15 in 2022, -₹1.90 in 2023, -₹9.79 in 2024, and ₹0.21 in 2025. The year-on-year growth rates show 958.0% growth in 2018, 36.0% growth in 2019, -22.5% decline in 2020, -204.3% decline in 2021, -110.9% decline in 2022, -265.2% decline in 2023, 415.3% growth in 2024, and -102.2% decline in 2025. Over a ten-year period, the company demonstrated extreme volatility in EPS, with the highest EPS of ₹13.03 in 2019 and the lowest (most negative) of -₹10.53 in 2021. The TTM EPS stands at ₹8.8 as of recent data.

The Dishman Carbogen Amcis P/E ratio has shown fluctuations over the ten-year period. At the end of recent fiscal years, the P/E ratio varied, with 2019 at 9.54x, 2020 at 1.13x, 2021 at 9.86x, 2022 at 13.01x, 2023 at 50.48x, 2024 at 28.55x, and 2025 at 28.0x. The mean historical P/E ratio over the last ten years has varied significantly. The current P/E ratio stands at 21.04 compared to the industry P/E of 409.97, reflecting that investor expectations are adjusting to near-term earnings headwinds. The Dishman Carbogen Amcis share price has been influenced by these valuation metrics. The Dishman Carbogen Amcis stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Dishman Carbogen Amcis Limited is a global pharmaceutical CDMO company listed on both the NSE and BSE, where the Dishman Carbogen Amcis share price reflects pharmaceutical outsourcing cycles, regulatory approval trends, and order book expansion within the CRAMS sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical outsourcing themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharmaceutical CDMO market